Target intelligence / Profile preview

Proton-coupled amino acid transporter 1 (PAT1 (SLC36A1))

Target
PAT1 (SLC36A1)
Molecular classification
Transporter, Solute carrier protein, Integral membrane protein
01

Overview

Proton-coupled amino acid transporters (PAT1/SLC36A1 and PAT2/SLC36A2) are integral membrane proteins responsible for symporting small neutral amino acids, such as glycine, alanine, and proline, with protons (H+) across cellular membranes. They are highly expressed in the luminal surface of the small intestine (PAT1) and also found in tissues such as brain, kidney, and lung (PAT2). These transporters display broad substrate specificity and low-affinity, high-capacity transport characteristics, making them attractive for prodrug strategies designed to enhance oral absorption and deliver therapeutic agents that mimic amino acid substrates. PATs have significant pharmacological relevance because their activity can influence the absorption and bioavailability of nutrients and drugs, particularly those that are amino acid-based or designed as prodrugs. Inhibition or competition at these transporters may affect drug-drug and nutrient-drug interactions in the gut.

Other names
hPAT1hPAT2SLC36A1SLC36A2proton-coupled amino acid symportersolute carrier family 36 member 1/2
02

Mechanism of action

Mediate drug absorption via H+ symport (proton-coupled drug/amino acid uptake across biological membranes) Drug molecules and prodrugs exploit transporter promiscuity for cellular uptake and improved bioavailability

03

Biological functions

Amino acid transmembrane transportNutrient absorption in the intestineCellular uptake of amino acids in tissues such as the brain, kidney, lung
04

Disease associations

Other (potential drug absorption and pharmacokinetics; no direct known links to major diseases but may impact drug efficacy and nutrient balance)
05

Safety considerations

Potential for drug-nutrient competition in the intestine, affecting absorption efficiency and leading to drug-drug/nutrient interactionsLimited known adverse events due to transporter inhibition or modulation; relevance primarily in pharmacokinetics
06

Interacting drugs

Gaboxadol

4 more in the full profile.

Beyond the preview

Go deeper on Proton-coupled amino acid transporter 1 (PAT1 (SLC36A1)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proton-coupled amino acid transporter 1 (PAT1 (SLC36A1)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call